Mitsubishi Tanabe Pharma Corporation

Hideki Horiuchi

Kenji Fukunaga

Masahiro Okuyama

Masanori Minoguchi

Norimitsu Hayashi

Daisuke Iijima

Kenji Usui

Koji Teshima

Toshihiko Tanaka

Tokushi Hanano

Takayuki Ishige

Nobuaki Fujimoto

Noriaki Itagaki

Masakazu Nakano

Shin-ichiro Ono

Sumie Sekiguchi

Shinichirou Ono

Shin-Ichiro Ono

Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Bicyclic heterocyclic compound

The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group,

Bicyclic or tricyclic heterocyclic compound

Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) wherein each symbol is as defined in the claims.

Benzimidazole compound and pharmaceutical use thereof

The present invention aims to provide a stable form of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, which is free of problems of water adsorption and the like, and shows superior water solubility. The present invention provides a crystal and a salt of (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide in a crystal form.

Benzimidazole compound in crystal form and salt thereof

Growing community of inventors

Osaka, Japan

Hideki Horiuchi